Navigation Links
A 23- Year- Old Gay Falls Victim To Meningitis C in Toronto

A 23- year- old gay man died of meningitis C in Toronto. Meningitis C is a meningococcal disease caused by bacterium Neisseria meningitidis.// It occurs rarely in Canada and is usually seen among teenagers and infants.

This disease has a record of 10 to 15 per cent fatality and 20 per cent of the survivors suffer lasting health problems, such as deafness and mental retardation.

Public health officials are anxious that anyone who came in close contact with him might be infected.

The deceased is supposed to have visited Crews/Tango Bar, a gay and lesbian meeting place, on November 17 and 18. The officials fear that those who had contacted his saliva by sharing drinks, utensils, cigarettes or kissing should be concerned and should get vaccinated.

''If they were at the bar and sat in the corner and didn't share anything, they're not at risk,'' said Dr. Vinita Dubey of Toronto Public Health.

Symptoms to look for are sudden high fever, chills, severe headache, nausea, vomiting and stiff neck.They usually show up within 2 to 10 days after exposure.

So far, there have been no other reported cases and hence it is being treated as a single case and not as an outbreak.

The deceased was admitted with his first symptoms on Nov. 21, and died five days later.

An associate of the diseased reported that the victim was an immigrant from St. Lucia.


PRI
'"/>




Page: 1

Related medicine news :

1. 46-Year-Old Canada Man Donates A Part Of His Liver To A Complete Stranger
2. Surgeons Retrieve ‘Three-Year-Old’ Forceps From Patient’s Abdoen
3. Apollo to Open Super-specialty Hospital in Oman by Year-end
4. Pancreatic Cancer Surgery Successful in 80-Year-Olds
5. 13-Year-Old Boy Is Latest Dengue Victim; Delhi Toll 47
6. Chronic Diseases said to Cause Falls in the Elderly
7. Vitamin D Supplements Reduce Incidence Of Falls In Elderly
8. Villagers Panic As Ice Falls From Sky
9. Suicide Rate Falls To Lowest Ever In UK
10. Outpatient List Falls From 41,000 To 6,000
11. Preventing Falls May Be Key to Avoiding Disability in Elderly
Post Your Comments:
(Date:12/2/2008)... , Amsterdam, 2 December 2008 - Elsevier announce...tters 2008 Supplement on the theme of "Second tri.... Second trimester abortion raises complex issues...providers of service delivery and the sometimes co... This issue of Reproductive Health Matters grew ...
(Date:12/2/2008)... , , WASHINGTON -- A new report from the Institu...ents, duty hours and workloads to decrease the cha...nce the learning environment for these doctors in ...educing residents, work hours from the maximum ave...il for Graduate Medical Education (ACGME) in 2003,...
(Date:12/2/2008)... , , SAN DIEGO, Dec. 2 S...est-growing exercise program for new moms and thei...r in baby care for more than 40 years, has signed ... , The new partnership will strengthen the com...ers and moms. , , "We are thrilled to have ...
(Date:12/2/2008)... Randomized Comparator Study to Evaluate Efficacy... , , WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswi...nounced that it plans to initiate the first clinic...citabine for injection) compared to Vidaza(R) (aza...ntermediate-2 or high-risk myelodysplastic syndrom...
Breaking Medicine News(10 mins):Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of pharmacology; the number of people taking medi...e recent years. It is however to be noted that com...nsequences, including death. // Several medicatio...can interact or work against each other. Patients ...
...een witness to the death of more than half a milli...e south of Russia.// According to the Federal Con... Jan 25 and Feb 1, almost 350,000 birds have died ...akhkent district, and 76,000 at the Makhachkalinsk...
... effective solutions to major problems. This is es...s now been found that addition of white vinegar to...ively destroy bacterial spores. // Researchers fr... this simple yet significant solution to bacterial...
...tution has warned about the possibility of a hemag... constitution of the much-dreaded avian influenza ...could enable human-human bird flu transmission by ...an receptors. The company has also alerted the WH...
Other Medicine News:Health News:Drug Combinations Could Be Dangerous 2Health News:Genetic Change In The H5N1 Virus Likely: Recombinomics Inc. 2
(Date:12/1/2008)... Dec. 1 GeoVax Labs, Inc...otechnology company developing,human vaccines for...Virus) and,other infectious agents, announced tod...Trials will take place in twelve sites across Nort...n collaboration with The National Institutes of,H...
(Date:11/28/2008)...OLIS, Nov. 28 Eli Lilly ...lemental New Drug Application (sNDA) from,the U.S...R) (duloxetine HCl),for the management of chronic...,the first half of 2009, adding data from a recent...itis pain of the knee. , The decision does ...
(Date:11/25/2008)...awareness can improve recovery , , Audio an...available on the Mayo Clinic News Blog. Please see... , ROCHESTER, Minn., Nov. 25 /PRNewswire-USNew...stroke patients don,t think they,re having a strok...til their condition worsens. The findings appear i...
(Date:11/25/2008)...E, Calif., Nov. 25 Pharm...that the company has completed a Phase 1,clinical...in-class,small-molecule Factor VIIa inhibitor. Th...unteers to evaluate the safety and pharmacologic e...I-27483 resulted in a linear dose,response in the...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Bioheart Founder Howard J Leonhardt Becomes Chairman of the Board of Directors 4022 1Bioheart Founder Howard J Leonhardt Becomes Chairman of the Board of Directors 4022 2Bioheart Founder Howard J Leonhardt Becomes Chairman of the Board of Directors 4022 3Bioheart Founder Howard J Leonhardt Becomes Chairman of the Board of Directors 4022 4NASA satellite measures pollution from east Asia to North America 2532 1NASA satellite measures pollution from east Asia to North America 2532 2NASA satellite measures pollution from east Asia to North America 2532 3Evanston Northwestern Healthcare Researchers Explain Effects of Large Scale Universal MRSA Surveillance Program That Supports Expanded Intervention 1543 1Evanston Northwestern Healthcare Researchers Explain Effects of Large Scale Universal MRSA Surveillance Program That Supports Expanded Intervention 1543 2Evanston Northwestern Healthcare Researchers Explain Effects of Large Scale Universal MRSA Surveillance Program That Supports Expanded Intervention 1543 3Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 1Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 2Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 3Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 4Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 5Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 6Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 7Emisphere Technologies Inc Announces 2007 Fourth Quarter and Year End Financial Results 4020 8
... Reported Safety & Tolerability Profile,in Sub...CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase I...of the American Diabetes,Association demonstrated ...dase-4 (DPP-4) in development by Bristol-Myers,Squ...), in,combination with metformin, exhibited a stat...
...Unique Mechanism of Action and Broad Potential for...A, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avige... innovating therapeutics,for the treatment of neur...pinion on Investigational Drugs has published an a...(ibudilast), a potential,first-in-class, non-opioi...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 2Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 3Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 4Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 5
Indicated for treatment of patella instability
OmoTrain is a unique support for the shoulder that promotes mobility and limits rotation.
... someone suffers an episode of acute low back pain...ickly restores functional mobility by providing po...,With just a few sizes that correspond directly to... will reduce inventory requirements while simplify...
Shoulder Immobilizer with Body Strap Navy blue cotton. Thumb look helps keep hand in neutral position. Padded, 2" blue pile material laminated to foam shoulder and body strap. Fits left or right. 5/p
Medicine Products: